SCHEMBL3031007

SCHEMBL3031007

CC(=O)N[C@@H](C)c1cc[c]cc1

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACACB O00763 19/20 0.49
ACACA Q13085 7/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3035562 1.00 ACACB (0.49) ACACBACACA
SCHEMBL316529 1.00 ACACB (0.49) ACACBACACA
SCHEMBL17923480 0.82 MEN1 (0.46) ACACBACACA
SCHEMBL13983797 0.79 ACACB (0.42) ACACBACACA
SCHEMBL540666 0.79 ACACB (0.65) ACACBACACA
SCHEMBL1754100 0.79 ACACB (0.65) ACACBACACA
SCHEMBL13778592 0.79 ACACB (0.56) ACACBACACA
SCHEMBL640385 0.79 ACACB (0.65) ACACBACACA
SCHEMBL27555544 0.78 CYP1A2 (0.40) ACACBACACA
SCHEMBL6966307 0.78 ACACB (0.54) ACACBACACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216791-A1 PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS ASTRAZENECA (SE) 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216791-A1 PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS BRAF, RAF1, ARAF ACACB 3667/4885ACACA 3311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.